1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Kovalenko, Pavlo L ^a   Zhang, Zhentao ^a   Cui, Min ^a   Clinton, Steve K ^b   Fleet, James C ^a  

^a PURDUE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CALCITRIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; NOTCH RECEPTOR; PROTEIN P53; SOMATOMEDIN C; STAT3 PROTEIN; STAT5B PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN; WNT PROTEIN; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; VITAMIN D;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL IMMORTALIZATION; CELL LINE; CELL LINE RWPE1; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE INDUCTION; GENE TARGETING; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VITAMIN D RESPONSIVE ELEMENT; CELL SURVIVAL; CELL TRANSFORMATION; CYTOLOGY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PROSTATE; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VITAMIN D;

EID: 76749134339     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-26     Document Type: Article

References (68)

1. Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995, 4:655-659.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990, 10:1307-1311.
3. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer. PLoS Med 2007, 4:e103. 10.1371/journal.pmed.0040103, 1831738, 17388667.
4. Fleet JC. Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 2008, 29:388-396. 10.1016/j.mam.2008.07.003, 2613446, 18755215.
5. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALAV-31. J Steroid Biochem Mol Biol 1996, 58:277-288. 10.1016/0960-0760(96)00030-1, 8836163.
6. Hedlund TE, Moffatt KA, Miller GJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: Evidence thqt the antiproliferative effects of 1 alpha,25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996, 137:1554-1561. 10.1210/en.137.5.1554, 8612485.
7. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997, 126:83-90. 10.1016/S0303-7207(96)03974-3, 9027366.
8. Fleet JC, Weaver CM, Heaney RP, Heaney RP. Molecular Regulation of Calcium Metabolism. Calcium in Human Health 2006, 163-190. Totowa, NJ: Humana Press.
9. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U937. Genes and Development 1996, 10:142-153. 10.1101/gad.10.2.142, 8566748.
10. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207. 10.1210/en.139.3.1197, 9492054.
11. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25- dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001, 165:1319-1324. 10.1016/S0022-5347(01)69892-6, 11257709.
12. Yang L, Yang J, Venkateswarlu S, Ko T, Brattain MG. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol 2001, 188:383-393. 10.1002/jcp.1125, 11473365.
13. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 1997, 42:31-41. 10.1023/A:1005772432465, 9116316.
14. Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, et al. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993, 4:201-208. 10.1097/00001813-199304000-00012, 8490200.
15. Veenstra TD, Windebank AJ, Kumar R. 1,25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-beta2 in neuroblastoma cells. Biochem Biophys Res Commun 1997, 235:15-18. 10.1006/bbrc.1997.6718, 9196027.
16. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, et al. Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D(3) Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation. Mol Endocrinol 2002, 16:1243-1256. 10.1210/me.16.6.1243, 12040012.
17. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005, 19:2685-2695. 10.1210/me.2005-0106, 16002434.
18. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004, 59:243-251. 10.1002/pros.20006, 15042599.
19. Qiao S, Tuohimaa P. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochem Biophys Res Commun 2004, 319:358-368. 10.1016/j.bbrc.2004.05.014, 15178414.
20. Guzey M, Luo J, Getzenberg RH. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells. J Cell Biochem 2004, 93:271-285. 10.1002/jcb.20182, 15368355.
21. Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ, et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 2006, 208:566-574. 10.1002/jcp.20692, 16741990.
22. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 2004, 92:131-141. 10.1016/j.jsbmb.2004.07.003, 15555907.
23. Dai X, Yamasaki K, Yang LJ, Sayama K, Shirakata Y, Tokumara S, et al. Keratinocyte G2/M growth arrest by 1,25-dihydroxyvitamin D3 is caused by Cdc2 phosphorylation through Wee1 and Myt1 regulation. Journal of Investigative Dermatology 2004, 122:1356-1364. 10.1111/j.0022-202X.2004.22522.x, 15175024.
24. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001, 154:369-387. 10.1083/jcb.200102028, 2150773, 11470825.
25. Shah S, Hecht A, Pestell R, Byers SW. Trans-repression of beta-catenin activity by nuclear receptors. Journal of Biological Chemistry 2003, 278:48137-48145. 10.1074/jbc.M307154200, 12972427.
26. Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008, 76:699-716. 10.1111/j.1432-0436.2008.00288.x, 18565101.
27. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research 2004, 64:6854-6857. 10.1158/0008-5472.CAN-04-2500, 15466172.
28. Zhang YX, Wang ZW, Ahmed F, Banerjee S, Li YW, Sarkar FH. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. International Journal of Cancer 2006, 119:2071-2077.
29. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002, 16:2-14. 10.1096/fj.01-0300rev, 11772931.
30. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009, 69:967-975. 10.1158/0008-5472.CAN-08-2307, 19141646.
31. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27:1883-1893. 10.1093/carcin/bgl041, 16624828.
32. Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, et al. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 2005, 24:6533-6544.
33. Campbell CL, Savarese DMF, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor. International Journal of Cancer 1999, 80:868-874.
34. Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, et al. 1, 25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009, 204:85-89. 10.1016/j.atherosclerosis.2008.08.020, 18834982.
35. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000, 87:214-220.
36. Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, Datta K. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res 2008, 68:8770-8778. 10.1158/0008-5472.CAN-08-1912, 2674365, 18974119.
37. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2573-2578. 10.1073/pnas.040337597, 15970, 10688880.
38. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF(165) antagonizes this effect. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:11432-11437. 10.1073/pnas.0403969101, 509218, 15273288.
39. Herman JG, Meadows GG. Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. International Journal of Oncology 2007, 30:1231-1238.
40. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions 2006, 160:1-40. 10.1016/j.cbi.2005.12.009, 16430879.
41. Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25-dihydroxyvitamin D-3 against oxidative stress in nonmalignant human prostate epithelial cells. International Journal of Cancer 2008, 122:2699-2706.
42. Wild AC, Moinova HR, Mulcahy RT. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. Journal of Biological Chemistry 1999, 274:33627-33636. 10.1074/jbc.274.47.33627, 10559251.
43. Frohlich DA, Mccabe MT, Arnold RS, Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 2008, 27:4353-4362. 10.1038/onc.2008.79, 18372916.
44. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin D-3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. Journal of Immunology 2000, 164:4443-4451.
45. Griffin MD, Dong X, Kumar R. Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch Biochem Biophys 2007, 460:218-226. 10.1016/j.abb.2007.01.034, 1945094, 17367745.
46. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O'Garra A. 1 alpha, 25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. Journal of Immunology 2001, 167:4974-4980.
47. Motrich RD, van Etten E, Depovere J, Riera CM, Rivero VE, Mathieu C. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. Journal of Autoimmunity 2009, 32:140-148. 10.1016/j.jaut.2009.02.002, 19269787.
48. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004, 172:S6-11. 10.1097/01.ju.0000142058.99614.ff, 15535435.
49. Mackern-Oberti JP, Maccioni M, Cuffini C, Gatti G, Rivero VE. Susceptibility of prostate epithelial cells to Chlamydia muridarum infection and their role in innate immunity by recruitment of intracellular Toll-like receptors 4 and 2 and MyD88 to the inclusion. Infection and Immunity 2006, 74:6973-6981. 10.1128/IAI.00593-06, 1698045, 16954392.
50. Schauber J, Oda Y, Buchau AS, Yun QC, Steinmeyer A, Zugel U, et al. Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J Invest Dermatol 2008, 128:816-824. 10.1038/sj.jid.5701102, 17943182.
51. Pfitzner E, Kliem S, Baus D, Litterst CM. The role of STATs in inflammation and inflammatory diseases. Current Pharmaceutical Design 2004, 10:2839-2850. 10.2174/1381612043383638, 15379672.
52. Cippitelli M, Santoni A. Vitamin D-3: a transcriptional modulator of the interferon-gamma gene. European Journal of Immunology 1998, 28:3017-3030. 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.0.CO;2-6, 9808170.
53. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFN gamma axis leading to Th1 response in experimental allergic encephalomyelitis. Journal of Neuroscience Research 2006, 83:1299-1309. 10.1002/jnr.20826, 16547967.
54. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006, 66:4516-4524. 10.1158/0008-5472.CAN-05-3796, 16618780.
55. Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha, 25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007, 6:2048-2056. 10.1158/1535-7163.MCT-06-0700, 2692592, 17604335.
56. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005, 97:31-36. 10.1016/j.jsbmb.2005.06.012, 16024246.
57. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in Human prostate adenocarcinoma. Prostate 2000, 42:73-78. 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G, 10579801.
58. Wu J, Smith LT, Plass C, Huang TH. ChIP-chip comes of age for genome-wide functional analysis. Cancer Res 2006, 66:6899-6902. 10.1158/0008-5472.CAN-06-0276, 16849531.
59. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS, et al. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci USA 1994, 91:11874-11878. 10.1073/pnas.91.25.11874, 45338, 7991549.
60. Bolstad BM, Collin F, Brettschneider J, Simpson K, Cope L, Irizarry RA, et al. Quality assessment of Affymetrix GeneChip data. Bioinformatics and Computational Biology Solutions Using R and Bioconductorù 2005, 42-43. Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S.
61. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 2004, 99:909-917.
62. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
63. Benjamini Y, Hochberg Y. Controlling false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 1995, 57:289-300.
64. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003, 4:R7. 10.1186/gb-2003-4-1-r7, 151291, 12540299.
65. Fleet JC, Eksir F, Hance KW, Wood RJ. Vitamin D-inducible calcium transport and gene expression in three Caco-2 cell lines. American Journal of Physiology-Gastrointestinal and Liver Physiology 2002, 283:G618-G625.
66. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
67. Cui M, Zhao Y, Hance KW, Shao A, Wood RJ, Fleet JC. Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2. J Cell Physiol 2009, 219:132-142. 10.1002/jcp.21657, 19097033.
68. Meyer MB, Watanuki M, Kim S, Shevde NK, Pike JW. The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol 2006, 20:1447-1461. 10.1210/me.2006-0031, 16574738.